

Xbrane AB (publ) today announces that the company's CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.

**Xbrane Biopharma AB today announces that Chief Financial Officer & Head of IR Anette Lindqvist has informed CEO Marin Åmark of her intention to scale back her operational work and thereby leave her position as CFO during the spring of 2025. Anette has been CFO for Xbrane since 2021 and will remain in her role until a replacement is secured. The recruitment process for a new CFO will begin immediately.**

"I would like to thank Anette for her work in recent years and wish her the best of luck with her plans to have more time for other things. The recruitment process for a new CFO will begin immediately and I feel confident that Anette, together with her competent employees, will guarantee a smooth handover process," says Martin Åmark, CEO.

"Xbrane is a fantastic company with very talented and knowledgeable colleagues with whom it has been a pleasure to work and whom I will miss a lot, while I look forward to having more time for other interests," says Anette Lindqvist CFO.

## Contacts

---

Martin Åmark, CEO

E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR

E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## About Us

---

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com)

Press Release  
26 November 2024 17:20:00 CET



---

*This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-26 17:20 CET.*

## **Attachments**

---

[Xbrane AB \(publ\) today announces that the company's CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.](#)